The purpose of this study is to determine if a biomarker assay obtained peripartum (1st-3rd trimester and post-partum) in patients with adult congenital heart disease can predict future risk of cardiovascular adverse events and determine if temporal changes in biomarkers levels throughout the peripartum period can provide a better risk prediction compared to samples taken at a single time-point.
Study Type
OBSERVATIONAL
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Number of Subjects with cardiovascular adverse events
A cardiovascular adverse event is defined as Documented atrial/ventricular arrhythmias, need for cardioversion, arrhythmia-related procedures (catheter ablation, implantation of pacemaker/defibrillator, anti-arrhythmia surgery), and heart failure hospitalization.
Time frame: Baseline
Number of Subject Deaths
Death will be determined as death due to end-stage heart failure, sudden cardiac death, thromboembolic death, and noncardiac death
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.